"The company#39;s formulations manufacturing facility located at Baddi, India, has received an EIR. The United States Food and Drug Administration (USFDA) had conducted an inspection at the facility from July 15 to 19, 2019," Cadila Healthcare said in a filing to BSE.Cadila Healthcare gets EIR from USFDA for Baddi facility
"The company#39;s formulations manufacturing facility located at Baddi, India, has received an EIR. The United States Food and Drug Administration (USFDA) had conducted an inspection at the facility from July 15 to 19, 2019," Cadila Healthcare said in a filing to BSE.
Subscribe to:
Post Comments (Atom)
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
-
In July, HCL Technologies had announced a Rs 4,000 crore buyback programme for FY19 at a price of Rs 1,100 per equity share.
No comments:
Post a Comment